Sibrotuzumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Sibrotuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetFAP
Clinical data
ATC code
  • none
Identifiers
CAS Number
  • 216669-97-5 ☒N
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Sibrotuzumab is a humanized monoclonal antibody intended for the treatment of cancer. It binds to FAP[1][2]

In 2003 it failed a phase II clinical trial for metastatic colorectal cancer.[3]

References[edit]

  1. ^ Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. (May 2003). "A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer". Clinical Cancer Research. 9 (5): 1639–47. PMID 12738716.
  2. ^ Kloft C, Graefe EU, Tanswell P, Scott AM, Hofheinz R, Amelsberg A, Karlsson MO (January 2004). "Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients". Investigational New Drugs. 22 (1): 39–52. doi:10.1023/B:DRUG.0000006173.72210.1c. PMID 14707493. S2CID 24877721.
  3. ^ Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jäger D, Renner C, et al. (February 2003). "Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer". Onkologie. 26 (1): 44–8. doi:10.1159/000069863. PMID 12624517. S2CID 29922209.